Trial · NCT07135973
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) | From baseline to 24 weeks | Drug related Grade ≥ 3 treatment emergent adverse events (TEAE) during the treatment period (24 weeks) |
| Secondary | Best overall Response (BoR) | Baseline to end of study i.e. 12 months | Best overall Response (BoR), defined as the proportion of patients who achieved complete response (CR) or partial response (PR) according to the NIH Consensus Criteria. |
| Secondary | Duration of Response (DOR) | Baseline to end of study i.e. 12 months | Duration of Response (DOR) calculated from time of initial PR or CR until documented progression, death, or new systemic therapy. |
| Secondary | Time to Response (TTR) | Baseline to end of study i.e. 12 months | |
| Secondary | Response by organ system (including GSR) | Baseline to end of study i.e. 12 months | |
| Secondary | Time taken for New Treatment (TTNT) or death | Baseline to end of study i.e. 12 months | |
| Secondary | Failure-free survival (FFS) | Baseline to end of study i.e. 12 months | |
| Secondary | Overall survival (OS) | Baseline to end of study i.e. 12 months | |
| Secondary | Change in Corticosteroid dose. | Baseline to end of study i.e. 12 months | |
| Secondary | Change in CNI dose | Baseline to end of study i.e. 12 months | |
| Secondary | Symptomatic improvement from baseline during treatment based on Lee Symptom Scale | Baseline to end of study i.e. 12 months | defined as a ≥7-point reduction from baseline in total symptom score on a scale of 0 to 100 which measures the symptoms of chronic GVHD, with higher scores indicating worse symptoms |
| Secondary | Pulmonary Function Test (PFT) | Baseline to end of study i.e. 12 months | Total lung capacity, Residual volume, Forced expiratory volume, Tidal volume |
| Secondary | Number of participants with treatment-emergent adverse events [TEAEs], serious TEAEs, and adverse events of special interest (AESIs) | Baseline to end of study i.e. 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07135973/registered